Reference pricing has the appeal of economic elegance: identify what efficient providers charge for a procedure, pay only that amount, and let competition sort the rest. The problem is that healthcare markets are not what the model requires.
What the citations often omit: CalPERS operates in California’s health system, which includes enough provider competition to make reference pricing credible as a steering mechanism. Employees facing cost-sharing differentials between high- and low-cost hospitals have somewhere to go. The mechanism requires the existence of low-cost alternatives within a reasonable distance and within the payer’s network.
MedPricer.org’s procedure-level rate data makes it possible to assess this precondition empirically before an employer adopts a reference pricing strategy. In markets where the rate distribution for a target procedure is highly compressed—where the gap between the highest- and lowest-priced in-network provider is 15%—reference pricing produces minimal savings and significant employee relations friction without meaningful steering effects. In markets where the distribution is wide—where some in-network hospitals charge three times what others charge for the same procedure—reference pricing can generate substantial savings if the lower-cost providers have adequate capacity and acceptable quality metrics.
The counterintuitive dynamic is what happens in concentrated markets where an employer adopts aggressive reference pricing. If the reference price is set at a level that excludes the dominant hospital system, employees face a network that is inadequate for their actual care needs. The employer eventually capitulates—renegotiates the benefit design, expands the reference price, or excludes the dominant system from the reference pricing program entirely. The dominant system, having successfully resisted the employer’s strategy, negotiates the next contract from a strengthened position. Reference pricing in concentrated markets can thus paradoxically enhance the leverage of exactly the providers it was designed to discipline.
This dynamic is not speculative. The history of tiered network and narrow network design in employer-sponsored insurance includes numerous cases where hospital systems successfully resisted through public campaigns, physician advocacy, and selective contract withdrawal—ultimately securing broader inclusion at higher rates than they would have accepted before the employer’s attempt at network discipline.
For hedge funds with positions in dominant hospital systems, this dynamic is relevant in a specific way. An employer-driven reference pricing initiative targeting a hospital system the fund is long on is not necessarily a threat. In concentrated markets, it may be the setup for a contract renewal outcome that demonstrates the system’s pricing power and reinforces the long thesis. The fund’s analytical task is to assess whether the market in which the targeted system operates is one where reference pricing can credibly operate—or one where the hospital will win the standoff.
MedPricer’s rate data supports this assessment by revealing both the extent of price dispersion in the market and the presence or absence of adequate lower-cost alternatives. A hospital system that is the sole provider of a procedure in its market—or whose closest competitors are consistently priced at comparable levels—is highly resistant to reference pricing. One that faces genuinely lower-cost, quality-equivalent competitors is more vulnerable. The rate data does not determine which category a given system falls into, but it narrows the analytical question considerably.
